VANCOUVER, BC, CANADA, February 26, 2026 / EINPresswire.com / — ARC Medical Inc. (“ARC”), a leader in surgical adhesion prevention innovation, plans to participate in the following events during the ...
The first in-human trial to use a novel ultrasound device to temporarily open the blood-brain barrier to deliver chemotherapy reveals that the procedure led to an increase in drug concentrations in ...
Please provide your email address to receive an email when new articles are posted on . Seventeen patients received albumin-bound paclitaxel infusion every 3 weeks for up to six cycles.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results